ehp550873 tab4

Medscape® www.medscape.com

		Tibia			Patella
No.	Wam (IMI)	IF^mlnu)	Logio IF/HF (%) No	HF*™ (nu)	LF*eim(nu)	log10 LF/HF |%)

Ali Model 1	413 -1.1 (-41 to 1.9)	1.2 (-18 to 4.2)	4.6 (-9 8 to 21.3)	398	-0.6 (-31 to 1.9)	0.6 (-1.9 to 3.1)	3X) (—8.9 to 16.5)
Model 2 No of metabolic abnormalities*	413 -0.9 (-3.8 to 2.1|	0.9 (-2.0 to 3.9)	3.3 (-10.7 to 19.5)	398	-0.6 (-3.1 to 1.9)	0.6 (-1.9 to 3.1)	30 (-8.7 to 163)
0	60 -30 (-12.5 to 4.9)	4.0 (—4.8 to 12.7)	22.6 (-20.3 to 88.4)	60	3.7 (-3.8 to 11.2)	-3.5 (-11.0 to 4.0)	-16.1 (-41.7 to 20.8)
1-2	220 01 (-3.7 to 3.9)	-0.03 (-3.9 to 38)	-30 (-19.7 to 17.2)	209	0.7 (-2.6 to 4.0)	-0.8 (-4.1 to 2.5)	-3.4 (-17.8 to 13.4)
*3	133 -2.7 (—7.9 to 2.5)	2.7 (-2 5 to 7.9)	156 (-10.5 to 49 4)	129	-39 (-0 2 to 0.5)*	3.9 (-0.4 to 83)*	212 (-1.9 to 49 8)*
pValue for trend	0896	0 920	0808		0.048	0.047	0.045

IQR increase: 17 pgTg for tibia lead and 15.4 pg/g lor patella lead. Model 1: adjusted lor age, cigarette smoking, alcobol consumption, room temperaturę, and season. Model 2: lurther adjusted lor BMI; lasting glucose; HOL cholesterol; tnglyceride; and use oł ft-btockers, calcium channel blockers. and^for ACE inhibitors.

*AB models adjusted as model 1. *p<0.1.

Source: Environ Health Perspect © 2006 National Institute of Environmental Health Sciences